Form 8-K - Current report:
SEC Accession No. 0001193125-26-168231
Filing Date
2026-04-22
Accepted
2026-04-22 06:22:26
Documents
16
Period of Report
2026-04-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d126526d8k.htm   iXBRL 8-K 55261
2 EX-2.1 d126526dex21.htm EX-2.1 864016
3 EX-10.1 d126526dex101.htm EX-10.1 33021
4 EX-10.2 d126526dex102.htm EX-10.2 33225
5 EX-99.1 d126526dex991.htm EX-99.1 161080
9 GRAPHIC g126526g0422040102347.jpg GRAPHIC 4223
  Complete submission text file 0001193125-26-168231.txt   1516738

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA amrx-20260422.xsd EX-101.SCH 3174
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE amrx-20260422_lab.xml EX-101.LAB 17233
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amrx-20260422_pre.xml EX-101.PRE 10808
19 EXTRACTED XBRL INSTANCE DOCUMENT d126526d8k_htm.xml XML 3518
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 26881238
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)